Potential of osteopontin in the management of epithelial ovarian cancer

1Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010; 103: 861-9. doi: 10.1038/sj.bjc.6605834 Weber GF Lett GS Haubein NC Osteopontin is a marker for cancer aggressiveness and patient survival Br J Cancer 2010 103 8619 10.1038/sj.bjc.6605834Open DOISearch in Google Scholar

2Hao C, Cui Y, Owen S, Li W, Cheng S, Jiang WG. Human osteopontin: potential clinical applications in cancer (Review). Int J Mol Med 2017; 39: 1327-37. doi: 10.3892/ijmm.2017.2964 Hao C Cui Y Owen S Li W Cheng S Jiang WG Human osteopontin: potential clinical applications in cancer (Review) Int J Mol Med 2017 39 132737 10.3892/ijmm.2017.2964Open DOISearch in Google Scholar

3Wei R, Wong JPC, Kwok HF. Osteopontin - a promising biomarker for cancer therapy. J Cancer 2017; 8: 2173-83. doi: 10.7150/jca.20480 Wei R Wong JPC Kwok HF Osteopontin - a promising biomarker for cancer therapy J Cancer 2017 8 217383 10.7150/jca.20480Open DOISearch in Google Scholar

4Zhao H, Chen Q, Alam A, Cui J, Suen KC, Soo AP, et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis 2018; 9: 356-70. doi: 10.1038/s41419-018-0391-6 Zhao H Chen Q Alam A Cui J Suen KC Soo AP The role of osteopontin in the progression of solid organ tumour Cell Death Dis 2018 9 35670 10.1038/s41419-018-0391-6Open DOISearch in Google Scholar

5Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. Jama-Journal Am Med Assoc 2002; 287: 1671-9. doi: 10.1001/jama.287.13.1671 Kim JH Skates SJ Uede T Wong KK Schorge JO Feltmate CM Osteopontin as a potential diagnostic biomarker for ovarian cancer Jama-Journal Am Med Assoc 2002 287 16719 10.1001/jama.287.13.1671Open DOISearch in Google Scholar

6Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res 2011; 4: 365-74. doi: 10.1158/1940-6207.CAPR-10-0195 Cramer DW Bast RC Berg CD Diamandis EP Godwin AK Hartge P Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens Cancer Prev Res 2011 4 36574 10.1158/1940-6207.CAPR-10-0195Open DOISearch in Google Scholar

7Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 7677-82. doi: 10.1073/pnas.0502178102 Mor G Visintin I Lai Y Zhao H Schwartz P Rutherford T Serum protein markers for early detection of ovarian cancer Proc Natl Acad Sci U S A 2005 102 767782 10.1073/pnas.0502178102Open DOISearch in Google Scholar

8Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008; 14: 1065-72. doi: 10.1158/1078-0432.CCR-07-1569 Visintin I Feng Z Longton G Ward DC Alvero AB Lai Y Diagnostic markers for early detection of ovarian cancer Clin Cancer Res 2008 14 106572 10.1158/1078-0432.CCR-07-1569Open DOISearch in Google Scholar

9Brakora KA, Lee H, Yusuf R, Sullivan L, Harris A, Colella T, et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 2004; 93: 361-5. doi: 10.1016/j.ygyno.2004.01.050 Brakora KA Lee H Yusuf R Sullivan L Harris A Colella T Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer Gynecol Oncol 2004 93 3615 10.1016/j.ygyno.2004.01.050Open DOISearch in Google Scholar

10Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004; 10: 3474-8. doi: 10.1158/1078-0432.CCR-03-0365 Schorge JO Drake RD Lee H Skates SJ Rajanbabu R Miller DS Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer Clin Cancer Res 2004 10 34748 10.1158/1078-0432.CCR-03-0365Open DOISearch in Google Scholar

11Lan Z, Fu D, Yu X, Xi M. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis. Fam Cancer 2016; 15: 221-30. doi: 10.1007/s10689-015-9847-3 Lan Z Fu D Yu X Xi M Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis Fam Cancer 2016 15 22130 10.1007/s10689-015-9847-3Open DOISearch in Google Scholar

12Hu Z-D, Wei T-T, Yang M, Ma N, Tang Q-Q, Qin B-D, et al. Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review. PLoS One 2015; 10: e0126444. doi: 10.1371/journal.pone.0126444 Hu Z-D Wei T-T Yang M Ma N Tang Q-Q Qin B-D Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review PLoS One 2015 10 e0126444 10.1371/journal.pone.0126444Open DOISearch in Google Scholar

13Bao LH, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci 2007; 14: 373-81. doi: 10.1007/s11373-006-9143-1 Bao LH Sakaguchi H Fujimoto J Tamaya T Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers J Biomed Sci 2007 14 37381 10.1007/s11373-006-9143-1Open DOISearch in Google Scholar

14Psyrri A, Kalogeras KT, Wirtz RM, Kouvatseas G, Karayannopoulou G, Goussia A, et al. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. J Transl Med 2017; 15: 1-11. doi: 10.1186/s12967-017-1134-7 Psyrri A Kalogeras KT Wirtz RM Kouvatseas G Karayannopoulou G Goussia A Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group J Transl Med 2017 15 111 10.1186/s12967-017-1134-7Open DOISearch in Google Scholar

15Hacker NF. State of the art of surgery in advanced epithelial ovarian cancer. Ann Oncol 2013; 24: 27-32. doi: 10.1093/annonc/mdt465 Hacker NF State of the art of surgery in advanced epithelial ovarian cancer Ann Oncol 2013 24 2732 10.1093/annonc/mdt465Open DOISearch in Google Scholar

16Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol 2016; 13: 255-61. doi: 10.1038/nrclinonc.2015.224 Narod S Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol 2016 13 25561 10.1038/nrclinonc.2015.224Open DOISearch in Google Scholar

17Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, et al. European society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery. Int J Gynecol Cancer 2017; 27: 1534-42. doi: 10.1097/IGC.0000000000001041 Querleu D Planchamp F Chiva L Fotopoulou C Barton D Cibula D European society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery Int J Gynecol Cancer 2017 27 153442 10.1097/IGC.0000000000001041Open DOISearch in Google Scholar

18Bristow RE, Karlan BY. Surgery for Ovarian Cancer: Principles and Practice 1st edition. Abingdon: Taylor & Francis; 2006. Bristow RE Karlan BY Surgery for Ovarian Cancer: Principles and Practice 1st edition Abingdon Taylor & Francis 2006Search in Google Scholar

19Chesnais M, Lecuru F, Mimouni M, Ngo C, Fauconnier A, Huchon C. A preoperative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer. PLoS One 2017; 12: 1-12. doi: 10.1371/journal.pone.0187245 Chesnais M Lecuru F Mimouni M Ngo C Fauconnier A Huchon C A preoperative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer PLoS One 2017 12 112 10.1371/journal.pone.0187245Open DOISearch in Google Scholar

20Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival - A review of the epidemiological literature. J Ovarian Res 2009; 2: 1-20. doi: 10.1186/1757-2215-2-13 Gupta D Lis CG Role of CA125 in predicting ovarian cancer survival - A review of the epidemiological literature J Ovarian Res 2009 2 120 10.1186/1757-2215-2-13Open DOISearch in Google Scholar

21Kobal B, Jerman KG, Karo J, Verdenik I, Cerne K. Relationship of ovarian cancer tumour markers concentration between local fluid and serum: Comparison of malignant to benign condition. Eur J Gynaecol Oncol 2018; 5: 743-50. doi: 10.12892/ejgo3848.2018 Kobal B Jerman KG Karo J Verdenik I Cerne K Relationship of ovarian cancer tumour markers concentration between local fluid and serum: Comparison of malignant to benign condition Eur J Gynaecol Oncol 2018 5 74350 10.12892/ejgo3848.2018Open DOISearch in Google Scholar

22Jerman KG, Kobal B, Jakimovska M, Verdenik I, Cerne K. Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy. World J Surg Oncol 2014; 12: 1-9. doi: 10.1186/1477-7819-12-278 Jerman KG Kobal B Jakimovska M Verdenik I Cerne K Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy World J Surg Oncol 2014 12 19 10.1186/1477-7819-12-278Open DOISearch in Google Scholar

23Lutz AM, Willmann JK, Cochran F V., Ray P, Gambhir SS. Cancer screening: A mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Med 2008; 5: 1287-97. doi: 10.1371/journal.pmed.0050170 Lutz AM Willmann JK Cochran F V. Ray P Gambhir SS Cancer screening: A mathematical model relating secreted blood biomarker levels to tumor sizes PLoS Med 2008 5 128797 10.1371/journal.pmed.0050170Open DOISearch in Google Scholar

24Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg 1996; 83: 6-14. doi: 10.1002/BJS.1800830104 Parsons SL Watson SA Steele RJ Malignant ascites Br J Surg 1996 83 614 10.1002/BJS.1800830104Open DOISearch in Google Scholar

25Stanojevic Z, Rancic G, Radic S, Potic-Zecevic N, Djordjevic B, Markovic M, et al. Pathogenesis of malignant ascites in ovarian cancer patients. Arch Oncol 2004; 12: 115-8. doi: 10.2298/AOO0402115S Stanojevic Z Rancic G Radic S Potic-Zecevic N Djordjevic B Markovic M Pathogenesis of malignant ascites in ovarian cancer patients Arch Oncol 2004 12 1158 10.2298/AOO0402115SOpen DOISearch in Google Scholar

26Weber GF. The cancer biomarker osteopontin: Combination with other markers. Cancer Genomics Proteomics 2011; 8: 263-88. PMID: 22086896 Weber GF The cancer biomarker osteopontin: Combination with other markers Cancer Genomics Proteomics 2011 8 26388 PMID: 22086896Search in Google Scholar

27Bandiera E, Zanotti L, Fabricio ASC, Bucca E, Squarcina E, Romani C, et al. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelinrelated peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clin Chem Lab Med 2013; 51: 1815-24. doi: 10.1515/cclm-2013-0151 Bandiera E Zanotti L Fabricio ASC Bucca E Squarcina E Romani C Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelinrelated peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis Clin Chem Lab Med 2013 51 181524 10.1515/cclm-2013-0151Open DOISearch in Google Scholar

28Sato S, Itamochi H. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy. Ther Adv Med Oncol 2014; 6: 293-304. doi: 10.1177/1758834014544891 Sato S Itamochi H Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy Ther Adv Med Oncol 2014 6 293304 10.1177/1758834014544891Open DOISearch in Google Scholar

29Skof E, Merlo S, Pilko G, Kobal B. The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer. Radiol Oncol 2016; 50: 341-6. doi: 10.1515/raon-2016-0034 Skof E Merlo S Pilko G Kobal B The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer Radiol Oncol 2016 50 3416 10.1515/raon-2016-0034Open DOISearch in Google Scholar

30Rutten MJ, Leeflang MM, Kenter GG, Mol BW, Buist M. Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. Cochrane Database Syst Rev 2014; 21. doi: 10.1002/14651858.CD009786. pub2 Rutten MJ Leeflang MM Kenter GG Mol BW Buist M Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer Cochrane Database Syst Rev 2014 21 10.1002/14651858.CD009786Open DOISearch in Google Scholar

31Cannistra SA. Cancer of the Ovary. N Engl J Med 1993; 329: 1550-9. doi: 10.1056/NEJM199311183292108 Cannistra SA Cancer of the Ovary N Engl J Med 1993 329 15509 10.1056/NEJM199311183292108Open DOISearch in Google Scholar

32Bookman MA, Ozols RF. Factoring outcomes in ovarian cancer. J Clin Oncol 1996; 14: 325-7. doi: 10.1200/JCO.1996.14.2.325 Bookman MA Ozols RF Factoring outcomes in ovarian cancer J Clin Oncol 1996 14 3257 10.1200/JCO.1996.14.2.325Open DOISearch in Google Scholar

33Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000; 5: 26-35. doi: 10.1634/theoncologist.5-1-26 Markman M Bookman MA Second-line treatment of ovarian cancer Oncologist 2000 5 2635 10.1634/theoncologist.5-1-26Open DOISearch in Google Scholar

34Graessmann M, Berg B, Fuchs B, Klein A, Graessmann A. Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3. Oncogene 2007; 26: 2840-50. doi: 10.1038/sj.onc.1210096 Graessmann M Berg B Fuchs B Klein A Graessmann A Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3 Oncogene 2007 26 284050 10.1038/sj.onc.1210096Open DOISearch in Google Scholar

35Hsieh I-S, Huang W-H, Liou H-C, Chuang W-J, Yang R-S, Fu W-M. Upregulation of drug transporter expression by osteopontin in prostate cancer cells. Mol Pharmacol 2013; 83: 968-77. doi: 10.1124/mol.112.082339 Hsieh I-S Huang W-H Liou H-C Chuang W-J Yang R-S Fu W-M Upregulation of drug transporter expression by osteopontin in prostate cancer cells Mol Pharmacol 2013 83 96877 10.1124/mol.112.082339Open DOISearch in Google Scholar

36Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, et al. Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer. Stem Cells Int 2015; 2015: 1-8. doi: 10.1155/2015/247892 Ng L Wan T Chow A Iyer D Man J Chen G Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer Stem Cells Int 2015 2015 18 10.1155/2015/247892Open DOISearch in Google Scholar

37Zhang T, Zhang DM, Zhao D, Hou XM, Yang TN. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer. J BUON 2014; 19: 742-8. PMID: 25261661 Zhang T Zhang DM Zhao D Hou XM Yang TN Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer J BUON 2014 19 7428 PMID: 25261661Search in Google Scholar

38Luo S-D, Chen Y-J, Liu C-T, Rau K-M, Chen Y-C, Tsai H-T, et al. Osteopontin involves cisplatin resistance and poor prognosis in oral squamous cell carcinoma. Biomed Res Int 2015; 2015: 1-13. doi: 10.1155/2015/508587 Luo S-D Chen Y-J Liu C-T Rau K-M Chen Y-C Tsai H-T Osteopontin involves cisplatin resistance and poor prognosis in oral squamous cell carcinoma Biomed Res Int 2015 2015 113 10.1155/2015/508587Open DOISearch in Google Scholar

39Faça VM, Ventura AP, Fitzgibbon MP, Pereira-Faça SR, Pitteri SJ, Green AE, et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One 2008; 3: e2425. doi: 10.1371/journal.pone.0002425 Faça VM Ventura AP Fitzgibbon MP Pereira-Faça SR Pitteri SJ Green AE Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains PLoS One 2008 3 e2425 10.1371/journal.pone.0002425Open DOISearch in Google Scholar